TERNTerns PharmaceuticalsTERN info
$10.21info6.02%24h
Global rank10083
Market cap$630.92M
Change 7d28.91%
YTD Performance58.05%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Terns Pharmaceuticals (TERN) Stock Overview

    Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of oncology, non-alcoholic steatohepatitis (NASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in clinical development for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

    TERN Stock Information

    Symbol
    TERN
    Address
    1065 East Hillsdale BoulevardFoster City, CA 94404United States
    Founded
    -
    Trading hours
    9:30 AM - 4:00 PM ET
    Website
    https://www.ternspharma.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    650 525 5535

    Terns Pharmaceuticals (TERN) Price Chart

    -
    Value:-

    Terns Pharmaceuticals Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $10.21
    N/A
    Market Cap
    $630.92M
    N/A
    Shares Outstanding
    61.79M
    N/A
    Employees
    46.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org